NASDAQ:IMMP - IMMUTEP LTD/S Stock Price, News, & Analysis

-0.08 (-4.71 %)
(As of 07/24/2019 04:38 AM ET)
Today's Range
Now: $1.62
50-Day Range
MA: $1.77
52-Week Range
Now: $1.62
Volume100,200 shs
Average Volume135,525 shs
Market Capitalization$54.90 million
P/E RatioN/A
Dividend YieldN/A
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMP



Sales & Book Value

Annual Sales$5.70 million
Book Value$0.95 per share



Market Cap$54.90 million
Next Earnings Date8/20/2019 (Estimated)
OptionableNot Optionable

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

IMMUTEP LTD/S (NASDAQ:IMMP) Frequently Asked Questions

What is IMMUTEP LTD/S's stock symbol?

IMMUTEP LTD/S trades on the NASDAQ under the ticker symbol "IMMP."

When is IMMUTEP LTD/S's next earnings date?

IMMUTEP LTD/S is scheduled to release their next quarterly earnings announcement on Tuesday, August 20th 2019. View Earnings Estimates for IMMUTEP LTD/S.

What price target have analysts set for IMMP?

2 brokerages have issued 1 year target prices for IMMUTEP LTD/S's stock. Their predictions range from $7.00 to $7.75. On average, they anticipate IMMUTEP LTD/S's stock price to reach $7.3750 in the next year. This suggests a possible upside of 355.2% from the stock's current price. View Analyst Price Targets for IMMUTEP LTD/S.

What is the consensus analysts' recommendation for IMMUTEP LTD/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMUTEP LTD/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMMUTEP LTD/S.

Has IMMUTEP LTD/S been receiving favorable news coverage?

News articles about IMMP stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMMUTEP LTD/S earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for IMMUTEP LTD/S.

Who are some of IMMUTEP LTD/S's key competitors?

What other stocks do shareholders of IMMUTEP LTD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMMUTEP LTD/S investors own include CHF Solutions (CHFS), Sophiris Bio (SPHS), Sarepta Therapeutics (SRPT), Verastem (VSTM), Celldex Therapeutics (CLDX), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Amarin (AMRN), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Who are IMMUTEP LTD/S's key executives?

IMMUTEP LTD/S's management team includes the folowing people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

How do I buy shares of IMMUTEP LTD/S?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IMMUTEP LTD/S's stock price today?

One share of IMMP stock can currently be purchased for approximately $1.62.

How big of a company is IMMUTEP LTD/S?

IMMUTEP LTD/S has a market capitalization of $54.90 million and generates $5.70 million in revenue each year. The biotechnology company earns $-9,870,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. View Additional Information About IMMUTEP LTD/S.

What is IMMUTEP LTD/S's official website?

The official website for IMMUTEP LTD/S is

How can I contact IMMUTEP LTD/S?

IMMUTEP LTD/S's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]

MarketBeat Community Rating for IMMUTEP LTD/S (NASDAQ IMMP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  435
MarketBeat's community ratings are surveys of what our community members think about IMMUTEP LTD/S and other stocks. Vote "Outperform" if you believe IMMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/24/2019 by Staff

Featured Article: Buy-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel